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Abstract Hepcidin is a peptide hormone that plays an
important role in iron metabolism. We have produced a
recombinant mouse hepcidin-1 by using baculovirus
expression system. Its expression yield was 25 lg/ml
when cell culture media were supplemented with a
protease inhibitor cocktail. The recombinant mouse
hepcidin-1 and synthetic human hepcidin-25 had similar
effects on reducing ferroportin expression in J774A cell
line and in peritoneal macrophages. However, synthetic
human hepcidin-25 was more efficient than recombi-
nant mouse hepcidin-1 in reducing iron concentration in
blood circulation (p \ 0.01).
Keywords Baculovirus expression system (BES) 
Ferroportin  Hepcidin  Iron metabolism
Introduction
Hepcidin is a cysteine-rich, antimicrobial peptide (Park
et al. 2001). In addition to its antimicrobial properties,
hepcidin has an iron regulatory function (Nemeth et al.
2003). Iron is an important component of O2-carrier
proteins such as hemoglobin and myoglobin (Cairo et al.
2006). Hepcidin transcript is translated into an 84-amino
acid prohepcidin that subsequently undergoes enzy-
matic cleavage to form mature hepcidin-25 (Park et al.
2001). Mice have two forms of hepcidin: hepcidin-1 and
hepcidin-2. Human hepcidin-25 and mouse hepcidin-1
are involved in iron storage and regulation (Lou et al.
2004). An excess of free iron can generate harmful
reactive oxygen species that increase the rate of cancer
and tissue damage (Hershko 2007). Hepcidin only binds
to a transmembrane iron exporter channel called
ferroportin. This results in ferroportin internalization
and lysosomal degradation. As a result, hepcidin can
decrease iron levels in blood circulation (Nguyen et al.
2006; Vyoral and Petrak 2005).
Iron chelators, such as deferoxamine, are used to
balance iron overloading conditions (Brittenham 2003).
Although deferoxamine is the preferred drug, it is
associated with several side effects such as deafness,
visual defects, or growth retardation (Hoffbrand 2005).
Therefore, there is a demand for alternative drugs that
are not associated with the aforementioned disadvan-
tages. Hepcidin as a natural peptide can be a more
efficient drug for treating iron overload. Moreover, it is
biodegradable and has low cytotoxic effects.
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We have already produced recombinant mouse hep-
cidin-1 in insect cells and showed that it resulted in iron
accumulation in J774A macrophage cells (Yazdani et al.
2011). In the present study, we have shown that a protease
inhibitor cocktail increases the yield of hepcidin produc-
tion up to 25 lg/ml in a baculovirus expression system
(BES). Our results showed a loss or inaccessibility of the
His-tag during hepcidin expression suggesting that anion
exchange chromatography is more suitable than nickel
column chromatography for purifying recombinant hep-
cidin. Finally, functional assays confirmed that effects of
recombinant hepcidin on ferroportin were similar to those
of its synthetic human counterpart. However, synthetic
human hepcidin-25 was more efficient than recombinant
mouse hepcidin-1 in reducing iron concentration in blood
circulation (p\0.01).
Materials and methods
Large-scale production of recombinant mouse
hepcidin-1
Molecular cloning and expression of mouse hepcidin-
1 in a BES was reported earlier (Yazdani et al. 2011).
For optimal expression and for decreasing the differ-
ent effects of cell proteases on recombinant mouse
hepcidin-1, cell culture medium was supplemented
with a protease inhibitor cocktail (Sigma-Aldrich) at
1.04 mM. This comprised 4-(2-aminoethyl)benzene-
sulfonyl fluoride hydrochloride, 0.8 lM aprotinin,
0.04 mM bestatin, 0.014 mM E-64, 0.02 mM leupep-
tin, and 0.015 mM pepstatin A.
Recombinant mouse hepcidin-1 expression was
investigated at 48–96 h after infection using 15 %
(v/v) SDS-PAGE and western blot analyses with
polyclonal anti-His-tag and anti-mouse hepcidin anti-
bodies (Alpha Diagnostic). Finally, Ni–NTA and
DEAE columns were used for purifying mouse hepci-
din-1. For functional assays, the His-tag was cleaved
from the recombinant mouse hepcidin-1 by using
tobacco etch virus (TEV) enzyme.
Effects of hepcidin on ferroportin expression
in cell culture
J774A cell line was used to study the effects of
hepcidin on ferroportin expression. The cells were
treated with ferric nitrilotriacetate (100 lM FeCl3 and
400 lM NTA) for 16 h to increase ferroportin expres-
sion (Delaby et al. 2005). Next, the cells were
separately incubated with 25 or 50 lg recombinant
mouse hepcidin-1 and synthetic human hepcidin-25 for
24 h. After incubation, the cells were washed 3 times
with phosphate buffered saline (PBS) and lysed in 2 %
(w/v) SDS solution containing protease inhibitor
cocktail. Ferroportin expression was examined by
12 % (v/v) SDS-PAGE and western blot analyses.
Rabbit anti-mouse ferroportin antibody (Alpha
Diagnostic) and anti-beta-actin antibody (Cell Signal-
ing Technology) were used for western blot analysis.
Ferroportin and beta-actin bands were detected using
ECL advance western blotting system.
Effects of hepcidin on iron circulation in animal
model
Three-to four-week-old male C57BL/6 mice were
from the Pasteur Institute of Iran. This study was
approved by the animal research committee of the
Golestan University of Medical Sciences (G/P/35/
1084). Mice were maintained on a normal iron diet for
2 weeks. The mice were then given a single intraperi-
toneal dose of 10, 25, or 50 lg of native mouse
hepcidin-1. Refolded synthetic human hepcidin-25
(Yazdani et al. 2011) in the same concentration was
used as a control. Each group included six mice. The
treated mice were sacrificed 24 h after the injection to
evaluate serum iron levels. Blood was collected using
cardiac puncture technique. Hemolysed sera were
excluded from the study, and serum iron levels were
evaluated using iron assay kit.
Effect of hepcidin on ferroportin expression
in peritoneal macrophages
Peritoneal macrophages were isolated and washed with
2 mM EDTA in PBS containing the protease inhibitor
cocktail. The macrophages were centrifuged at
5009g and lysed with lysis buffer [150 mM NaCl,
20 mM Tri/HCl, 2 mM EDTA, 2 % (w/v) SDS, and
protease inhibitor cocktail]. The lysates were centri-
fuged at 2,0009g for 10 min to eliminate cell debris,
and supernatants were tested using BCA protein assay
kit to estimate the total protein concentration in all
groups. Ferroportin expression was examined by 12 %
(v/v) SDS-PAGE and western blotting. The details of
the experiments are mentioned in the preceding section.
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Results and discussion
Expression and increase in the yield
of recombinant mouse hepcidin-1
In our previous study (Yazdani et al. 2011), we
produced recombinant mouse hepcidin-1 in the BES
(Fig. 1a). The modified coding sequence of the
recombinant mouse hepcidin-1 is a 333-bp segment
that encodes a small secretory peptide having a
theoretical molecular mass of 12.5 kDd (Fig. 1b).
During secretion, the produced recombinant mouse
hepcidin-1 is susceptible to protease activities within the
expressing cells and within the cell culture medium.
Fig. 1 a Schema for the production of recombinant mouse
hepcidin-1 in baculovirus expression system. Hepcidin cDNA
was cloned into pFastBac HT B vector, and recombinant bacmid
was produced using homologous recombination in DH10
bacteria. Insect Sf9 cell line was used for producing recombinant
baculovirus. For hepcidin expression, MOI 10 was used in
monolayer Sf9 cells. Infected insect cells in cell culture media
with or without protease inhibitor cocktail were harvested at
48 h after infection. Finally, Ni–NTA and DEAE columns were
used to purify the recombinant mouse hepcidin-1. The amount
of purified recombinant mouse hepcidin is labeled as ?. b The
diagram of the complete coding sequence of recombinant mouse
hepcidin-1. Restriction enzyme sites were used for direct
cloning of hepcidin cDNA into a multiple cloning site of vector.
The His-tag sequence allowed the expressed hepcidin to be
purified using Ni–NTA column. The TEV recognition site
encoded a TEV protease site for His-tag removal after hepcidin
purification
Biotechnol Lett
123
Several studies on the BES have shown that the viral
genome expresses several families of proteases such as
carboxyl peptidases (Gotoh et al. 2001; Licari and
Bailey 1991). Baculoviruses that have deletions in the
p26, p10, and p74 genes show higher expression of the
recombinant peptide (Hitchman et al. 2010). Green-
shields et al. (2008) reported that recombinant Sal1
hepcidin was not detected by western blot of the BES
even though hepcidin mRNA was isolated from the
infected insect cells. These reports indicated that
baculoviruses and insect cells have different factors
that affect the production of the recombinant peptide.
In the absence of protease inhibitors, there was no
correlation between the results obtained from SDS-
PAGE and those obtained from western blot analysis.
Signals obtained by western blot analysis using anti-
His-tag antibody significantly decreased. The yield of
hepcidin expression was between 15 to 20 lg/ml
(Yazdani et al. 2011). When the cell culture medium
was supplemented with a protease inhibitor cocktail to
minimize the effects of proteases on the yield of
recombinant mouse hepcidin-1, the yield increased to
25 lg/ml.
Optimum production time is another important
factor that affects the yield of hepcidin production.
Our previous report showed that optimum production
time of recombinant hepcidin is 72 h after infection
(Yazdani et al. 2011). In this study, we took samples at
48, 72, and 96 h after infection to determine optimal
production time for recombinant mouse hepcidin-1.
Insect cells were therefore transfected with recombi-
nant baculovirus at multiplicity of infection (MOI) 10
in the presence of the protease inhibitor cocktail.
Hepcidin expression was then investigated using SDS-
PAGE and western blot analyses with anti-His-tag and
anti-mouse hepcidin antibodies (Fig. 2).
Fig. 2 Expression analysis of the recombinant mouse hepcidin-1.
Expressed proteins in cell culture medium were electrophoresed on
SDS-PAGE (a) and then confirmed using anti-His-tag (b) and anti-
hepcidin (c) polyclonal antibodies. Insect cells infected with MOI
10 and production of recombinant mouse hepcidin-1 was studied at
48, 72 and 96 h after infection. Lanes A, B and C indicate protein
analysis at 48, 72, and 96 h after infection, respectively
Fig. 3 Effects of hepcidin on ferroportin expression in iron-
treated J774A cell line. Proteins were examined on SDS-PAGE
(a). The position and sizes (in kDa) of molecular markers are
indicated on the right as Mar. Lane A corresponds to the total
protein in J774A cell line treated only with Fe-NTA as a
negative control. Ferroportin band is clearly observed to be
*68 kDa. Lanes B and C indicate cells cotreated with iron and
25 and 50 lg of the recombinant mouse hepcidin-1. Lanes D and
E show the results of the same treatment with synthetic human
hepcidin-25. After electrophoresis, proteins were transferred to
a nitrocellulose membrane and ferroportin was confirmed using
rabbit anti-mouse ferroportin antibody (b). Lane A indicates
cells treated with Fe-NTA as negative control. Other lanes are
similar to part (a)
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SDS-PAGE analysis showed the same band corre-
sponding to the recombinant mouse hepcidin-1.
However, detailed assessments with western blot
analysis showed that the protease inhibitor cocktail
did not completely protect the hepcidin structure
(Fig. 2). At 48 h after infection, western blot analysis
with anti-His-tag antibody showed a high-intensity
band corresponding to the recombinant mouse hepci-
din-1 (Fig. 2b). Reduction in western blot signals can
be explained by the removal or degradation of His-tag
from some of recombinant hepcidin molecules during
or after the expression in the insect cell line. Another
possibility is that the His-tag might be hidden by the
3-dimensional structure of the hepcidin protein. Thus,
the present data indicates that the optimum time for
native recombinant mouse hepcidin-1 expression is
48 h after infection. Because of the loss of His-tag or
His-tag inaccessibility, purification method such as
nickel column chromatography, which is based on the
affinity of histidine for nickel ion, was not suitable for
hepcidin purification. Therefore, anion exchange
chromatography, which depends on charge–charge
interactions between the recombinant mouse hepci-
din-1 and the charges immobilized on the resin, was
used for hepcidin purification.
Functional studies on recombinant mouse
hepcidin-1
For functional analysis, recombinant mouse hepcidin-
1 was purified using a DEAE column and the His-tag
was cleaved using TEV protease. Next, the synthetic
human hepcidin was refolded as a control (Yazdani
et al. 2011). Functional assessments were performed
by evaluating the effects of hepcidin on ferroportin
expression in iron-treated J774A cell line. The effects
of hepcidin on iron concentration in blood circulation
and ferroportin expression in peritoneal macrophage
cells were also studied.
The effects of hepcidin on ferroportin expression in
cell culture are summarized in Fig. 3. Both recombi-
nant mouse and synthetic human hepcidins signifi-
cantly decrease the ferroportin band in cells cotreated
with iron and hepcidin peptides. Reduction in ferro-
portin expression was dose dependent; hence, 50 lg
both hepcidins had higher effects on ferroportin
expression. The difference between the two types of
hepcidins was not significant.
For in vivo assays, mice maintained on normal iron
diet were given a single doses of 10, 25 or 50 lg
recombinant mouse hepcidin-1 and synthetic human
hepcidin-25 separately. The serum iron levels in
treated mice, assessed 24 h after injection, were
decreased in both groups. Mice treated with synthetic
human hepcidin-25 also showed a progressive
decrease in serum iron levels (Fig. 4). Moreover, our
findings showed an increase in hepcidin concentration
resulted in further reduction in serum iron levels in
both the treated groups (p \ 0.01). However, no
significant difference was observed between 25 and
50 lg of recombinant mouse hepcidin-1 with respect
to the reduction in serum iron levels (p = 0.167).
The differences in the effects of recombinant mouse
and synthetic human hepcidins on iron concentration
could be explained by two scenarios. First, because of
the larger size and presence of four disulphide bonds,
recombinant mouse hepcidin-1 may become aggre-
gated after infusion into the mice peritoneal cavity.
However, the refolded synthetic human hepcidin-25
has a smaller size (2.5 kDa) and is diffused after
peritoneal injection. Second, the recombinant mouse
hepcidin-1 may require additional post-translational
Fig. 4 Effects of hepcidin on iron concentration. Mice received
a single dose of either 10, 25 or 50 lg recombinant mouse and
synthetic human hepcidins separately. Data are expressed as the
mean ± SEM of 6 mice, and p values are obtained using t test.
The significant level for p value is p B 0.05(* p \ 0.05). No
significant difference was observed between 25 and 50 lg
recombinant mouse hepcidin-1 (p = 0.167)
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modifications such as enzymatic cleavage during secre-
tion to attain its complete function (Ravasi et al. 2012).
To investigate the underlying differences between
recombinant mouse hepcidin-1 and synthetic human
hepcidin-25, we assessed the effects of hepcidin on
ferroportin expression as a target molecule. When
mice were treated with 50 lg hepcidin, no significant
difference was observed with respect to the reduction
of ferroportin expression between the two forms of
hepcidins (Fig. 5a). Moreover, these results showed
that reduction in ferroportin expression was dose-
dependent; it was higher in mice treated with 50 lg
recombinant mouse hepcidin-1 than in mice treated
with 25 lg recombinant mouse hepcidin-1 (Fig. 5b).
Conclusion
A protease inhibitor cocktail can increase the yield of
recombinant mouse hepcidin-1 to up to 25 lg/ml in
BES. Further, the optimum production time for
recombinant mouse hepcidin-1 was 48 h. Because of
the loss of His-tag or His-tag inaccessibility during
hepcidin expression, anion exchange chromatography
was considered to be a more suitable approach for
purifying recombinant mouse hepcidin-1. Recombi-
nant mouse hepcidin-1 significantly decreased ferro-
portin expression in the J774A cell line although the
difference between recombinant mouse hepcidin-1
and synthetic human hepcidin-25 was not significant.
However, after infusion into the mouse peritoneal
cavity, recombinant mouse hepcidin-1 mainly showed
a local activity on peritoneal macrophages. Synthetic
human hepcidin-25, that has a tendency to form an
aggregated peptide in biological samples, not only had
a local effect but also had effects throughout the body
and significantly decreased iron levels in blood
circulation in comparison to the recombinant mouse
hepcidin-1.
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